U.S. markets open in 9 hours 27 minutes
S&P Futures
3,882.25+14.75(+0.38%)Dow Futures
31,459.00+101.00(+0.32%)Nasdaq Futures
13,138.50+83.25(+0.64%)
57967 (RLF)
YHD - YHD Delayed Price. Currency in USD
Add to watchlist
At close: 6:07PM EDT
| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
- GlobeNewswire
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
At FDA’s request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for patients who meet the criteria. RADNOR, Pa. and GENEVA, June 24, 2020 (GLOBE NEWSWIRE) -- NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.
© 2021 Verizon Media. All rights reserved.
